Rokote Laboratories Finland Ltd has decided to update its intranasal vaccine because the SARS-CoV-2 BA.4 and BA.5 virus variants have become more common. Therefore, the launch of the clinical trials will be moved to 2023. SARS-CoV-2 appears to be here to stay and able...

read more